Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer And Lpath To Partner On Antibody For Wet Age-Related Macular Degeneration

This article was originally published in The Pink Sheet Daily

Executive Summary

Option deal provides $14 million upfront plus cost-sharing arrangement for previously cash-strapped biotech.

You may also be interested in...



FDA Lifts Clinical Hold On Lpath’s Wet-AMD Drug Isonep

The San Diego biotech gets clearance from regulatory authorities to restart Phase II trials for its lead compound after a clinical hold delayed progress.

Financings Of The Fortnight: More IPOs But More Haircuts As Well

Initial public offerings by life sciences companies spanned the alphabet over the past two weeks, but each of three IPOs had one common factor - significant discounts in opening share prices.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel